Abstract | OBJECTIVES: PATIENTS AND METHODS: Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males. All patients were required to have MNE. The patients were randomly divided into two groups: the first group was given oral melt 120 µg and the second group 240 µg, for 2 weeks. All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks. As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered. RESULTS: There was no significant difference between the 120 µg and 240 µg patients in terms of response. The oxybutynin group showed a higher rate of full and partial responses (45% success) compared with the placebo group (17% success), P < 0.01. The responders to combined oxybutynin and desmopressin had significantly lower bladder volume and wall thickness index than the other patients. CONCLUSIONS: Our findings highlight that anticholinergic agents may play an important role for a subset of children with enuresis who have a restricted bladder capacity and thickened bladder wall. Ultrasonography-measured bladder variables can provide useful predictive clues for MNE. Predictive factors can help to differentiate treatment subtypes and guide clinical management in primary nocturnal enuresis.
|
Authors | Paolo Montaldo, Lucia Tafuro, Monica Rea, Valeria Narciso, Azzurra C Iossa, Roberto Del Gado |
Journal | BJU international
(BJU Int)
Vol. 110
Issue 8 Pt B
Pg. E381-6
(Oct 2012)
ISSN: 1464-410X [Electronic] England |
PMID | 22313792
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
Chemical References |
- Antidiuretic Agents
- Mandelic Acids
- Deamino Arginine Vasopressin
- oxybutynin
|
Topics |
- Adolescent
- Antidiuretic Agents
(therapeutic use)
- Child
- Deamino Arginine Vasopressin
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Mandelic Acids
(therapeutic use)
- Nocturnal Enuresis
(drug therapy)
|